세계의 이상지질혈증 치료 시장 보고서(2025년)

Lipid disorder treatment encompasses a holistic approach involving lifestyle adjustments, medications, and regular monitoring to manage conditions such as high cholesterol and triglycerides. The goal is to mitigate the risk of atherosclerosis and its associated complications, including heart disease and stroke.

Key medications used in lipid disorder treatment include atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, and others. Atorvastatin, classified as an HMG-CoA reductase inhibitor, is utilized for various lipid disorders, including familial combined hyperlipidemia, familial defective apolipoprotein B-100, familial dysbetalipoproteinemia, familial hypertriglyceridemia, heterozygous familial hypercholesterolemia, among others. This medication is made available through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The lipid disorder treatment market research report is one of a series of new reports from The Business Research Company that provides lipid disorder treatment market statistics, including lipid disorder treatment industry global market size, regional shares, competitors with a lipid disorder treatment market share, detailed lipid disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lipid disorder treatment industry. This lipid disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lipid disorder treatment market size has grown rapidly in recent years. It will grow from $10.69 billion in 2024 to $12.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increase in adoption of sedentary lifestyle, rise in working population, rise in awareness regarding the disease and treatment, increase in on-the-desk jobs, growth of familial combined hyperlipidemia incidence.

The lipid disorder treatment market size is expected to see rapid growth in the next few years. It will grow to $18.82 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growing cases of obesity and high cholesterol, increase in prevalence of cardiovascular diseases, growing occurrence of high cholesterol causing heart diseases, rise in the demand for safe and efficient treatments, excessive consumption of alcohol and smoking. Major trends in the forecast period include technological advancements in drug development, product innovation, increase in investments in business expansion, technological advancement in the treatment facilities, clinical advancements.

The forecast of 11.8% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of PCSK9 inhibitors and lipoprotein apheresis systems sourced from France and Italy, exacerbating cardiovascular disease management expenses and limiting access to advanced therapies. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the lipid disorder treatment market is expected to be propelled by the increasing prevalence of obesity and high cholesterol. Obesity, characterized by excessive body fat accumulation, and high cholesterol, denoting elevated cholesterol levels in the blood, pose significant health risks and are on the rise due to various factors including unhealthy diets, sedentary lifestyles, genetic predispositions, and environmental influences. Lipid disorder treatment plays a crucial role in managing obesity and high cholesterol by employing pharmacological interventions alongside lifestyle modifications, weight management strategies, patient education, and multidisciplinary care. For instance, according to the World Obesity Atlas 2022 published by the World Obesity Federation, it is projected that by 2030, one billion people globally will be living with obesity, with that number escalating to 4 billion people, or 51% of the global population, by 2035. Hence, the escalating cases of obesity and high cholesterol are key drivers fueling the growth of the lipid disorder treatment market.

Major companies in this market are focusing on developing innovative therapies to address the need for more effective and targeted treatments for managing high cholesterol levels. One such example is the development of proprotein convertase subtilisin type 9 (PCSK9) inhibitors, which enhance the removal of LDL cholesterol from the bloodstream, thus reducing the risk of cardiovascular events in high-risk patients. For instance, in March 2024, Regeneron Pharmaceuticals Inc. received FDA approval for Praluent (alirocumab) injection to treat heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. This medication blocks the binding of PCSK9 to the LDL receptor, increasing the quantity of LDL receptors on liver cell surfaces and facilitating the clearance of LDL cholesterol from the bloodstream.

In July 2023, Eli Lilly and Company's acquisition of Versanis contribute to bolstering companies' portfolios in the cardiometabolic disease space, particularly in the obesity drug pipeline. Versanis, a clinical-stage biopharmaceutical company specializing in treating cardiometabolic diseases, enhances Lilly's capabilities in addressing the challenges posed by obesity and related disorders.

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited.

North America was the largest region in the lipid disorder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lipid disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lipid disorder treatment market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, lifestyle counseling, medication management, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The lipid disorder treatment market also includes sales of fibrates, niacin, bile acid sequestrants and omega-3 fatty acids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lipid Disorder Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lipid disorder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lipid disorder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lipid disorder treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Atorvastatin; Fluvastatin; Rosuvastatin; Simvastatin; Pravastatin; Other Drugs
• 2) By Indication: Familial Combined Hyperlipidemia; Familial Defective Apolipoprotein B-100; Familial Dysbetalipoproteinemia; Familial Hypertriglyceridemia; Heterozygous Familial Hypercholesterolemia; Other Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Atorvastatin: Generic Atorvastatin; Brand-Name Atorvastatin ( Lipitor)
• 2) By Fluvastatin: Generic Fluvastatin; Brand-Name Fluvastatin ( Lescol)
• 3) By Rosuvastatin: Generic Rosuvastatin; Brand-Name Rosuvastatin ( Crestor)
• 4) By Simvastatin: Generic Simvastatin; Brand-Name Simvastatin ( Zocor)
• 5) By Pravastatin: Generic Pravastatin; Brand-Name Pravastatin ( Pravachol)
• 6) By Other Drugs: Ezetimibe; Pcsk9 Inhibitors ( Alirocumab, Evolocumab); Fibrates ( Gemfibrozil, Fenofibrate); Niacin (Vitamin B3); Omega-3 Fatty Acids ( Icosapent Ethyl)
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; AstraZeneca Plc; Fresenius SE & Co. KGaA; Abbott Laboratories Inc.; Novartis AG; GlaxoSmithKline Plc; Wockhardt Ltd.; Eli Lilly and Company; Amgen Inc.; Boehringer-Ingelheim International GmbH; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Mylan N.V.; Kaneka Corporation; Sun Pharmaceutical Industries Ltd.; Glenmark Pharmaceuticals Limited; Emcure Pharmaceuticals Limited; Kowa Pharmaceuticals America Inc.; Concord Biotech Limited; Biocon Ltd.; Ranbaxy Laboratories Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lipid Disorder Treatment Market Characteristics

3. Lipid Disorder Treatment Market Trends And Strategies

4. Lipid Disorder Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Lipid Disorder Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lipid Disorder Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lipid Disorder Treatment Market Growth Rate Analysis
• 5.4. Global Lipid Disorder Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lipid Disorder Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lipid Disorder Treatment Total Addressable Market (TAM)

6. Lipid Disorder Treatment Market Segmentation

• 6.1. Global Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Fluvastatin
• Rosuvastatin
• Simvastatin
• Pravastatin
• Other Drugs
• 6.2. Global Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial Combined Hyperlipidemia
• Familial Defective Apolipoprotein B-100
• Familial Dysbetalipoproteinemia
• Familial Hypertriglyceridemia
• Heterozygous Familial Hypercholesterolemia
• Other Indications
• 6.3. Global Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Atorvastatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Atorvastatin
• Brand-Name Atorvastatin (Lipitor)
• 6.5. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Fluvastatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Fluvastatin
• Brand-Name Fluvastatin (Lescol)
• 6.6. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Rosuvastatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Rosuvastatin
• Brand-Name Rosuvastatin (Crestor)
• 6.7. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Simvastatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Simvastatin
• Brand-Name Simvastatin (Zocor)
• 6.8. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Pravastatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Pravastatin
• Brand-Name Pravastatin (Pravachol)
• 6.9. Global Lipid Disorder Treatment Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ezetimibe
• PCSK9 Inhibitors (Alirocumab, Evolocumab)
• Fibrates (Gemfibrozil, Fenofibrate)
• Niacin (Vitamin B3)
• Omega-3 Fatty Acids (Icosapent Ethyl)

7. Lipid Disorder Treatment Market Regional And Country Analysis

• 7.1. Global Lipid Disorder Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lipid Disorder Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lipid Disorder Treatment Market

• 8.1. Asia-Pacific Lipid Disorder Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lipid Disorder Treatment Market

• 9.1. China Lipid Disorder Treatment Market Overview
• 9.2. China Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lipid Disorder Treatment Market

• 10.1. India Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lipid Disorder Treatment Market

• 11.1. Japan Lipid Disorder Treatment Market Overview
• 11.2. Japan Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lipid Disorder Treatment Market

• 12.1. Australia Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lipid Disorder Treatment Market

• 13.1. Indonesia Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lipid Disorder Treatment Market

• 14.1. South Korea Lipid Disorder Treatment Market Overview
• 14.2. South Korea Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lipid Disorder Treatment Market

• 15.1. Western Europe Lipid Disorder Treatment Market Overview
• 15.2. Western Europe Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lipid Disorder Treatment Market

• 16.1. UK Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lipid Disorder Treatment Market

• 17.1. Germany Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lipid Disorder Treatment Market

• 18.1. France Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lipid Disorder Treatment Market

• 19.1. Italy Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lipid Disorder Treatment Market

• 20.1. Spain Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lipid Disorder Treatment Market

• 21.1. Eastern Europe Lipid Disorder Treatment Market Overview
• 21.2. Eastern Europe Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lipid Disorder Treatment Market

• 22.1. Russia Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lipid Disorder Treatment Market

• 23.1. North America Lipid Disorder Treatment Market Overview
• 23.2. North America Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lipid Disorder Treatment Market

• 24.1. USA Lipid Disorder Treatment Market Overview
• 24.2. USA Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lipid Disorder Treatment Market

• 25.1. Canada Lipid Disorder Treatment Market Overview
• 25.2. Canada Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lipid Disorder Treatment Market

• 26.1. South America Lipid Disorder Treatment Market Overview
• 26.2. South America Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lipid Disorder Treatment Market

• 27.1. Brazil Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lipid Disorder Treatment Market

• 28.1. Middle East Lipid Disorder Treatment Market Overview
• 28.2. Middle East Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lipid Disorder Treatment Market

• 29.1. Africa Lipid Disorder Treatment Market Overview
• 29.2. Africa Lipid Disorder Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lipid Disorder Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lipid Disorder Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lipid Disorder Treatment Market Competitive Landscape And Company Profiles

• 30.1. Lipid Disorder Treatment Market Competitive Landscape
• 30.2. Lipid Disorder Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Lipid Disorder Treatment Market Other Major And Innovative Companies

• 31.1. Fresenius SE & Co. KGaA
• 31.2. Abbott Laboratories Inc.
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline Plc
• 31.5. Wockhardt Ltd.
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Boehringer-Ingelheim International GmbH
• 31.9. Viatris Inc.
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Mylan N.V.
• 31.13. Kaneka Corporation
• 31.14. Sun Pharmaceutical Industries Ltd.
• 31.15. Glenmark Pharmaceuticals Limited

32. Global Lipid Disorder Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lipid Disorder Treatment Market

34. Recent Developments In The Lipid Disorder Treatment Market

35. Lipid Disorder Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Lipid Disorder Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lipid Disorder Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lipid Disorder Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer